{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT00504608: Phase 1/Phase 2 Interventional Completed Infertility Implantation Failure
(2003)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT00658437: Phase 2 Interventional Completed Melanoma
(2008)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00032305: Phase 2/Phase 3 Interventional Completed Ulcerative Colitis
(2002)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
USAN:HEMOGLOBIN GLUTAMER-256 (HUMAN) [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:insulin argine [INN]
Source URL:
Class:
PROTEIN
Insulin Argine is a human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The primary activity of insulin, including Insulin Argine, is the regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin Argine differs from human insulin in that two arginines are added to the C-terminus of the B-chain. Unfortunately Insulin Argine failed to demonstrate superior efficacy to regular human insulin and clinical development was discontinued
Class:
PROTEIN
Ilatreotide was developed as a somatostatin receptor agonist with potential for treating gastroenteropancreatic tumors. It is an orally active pituitary and guts hormonal secretion inhibitor.
Status:
Investigational
Source:
NCT00445965: Phase 2 Interventional Completed Brain and Central Nervous System Tumors
(2006)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02534922: Phase 1 Interventional Unknown status Ovarian Cancer
(2016)
Source URL:
Class:
PROTEIN
